Home › Neuroendocrine Carcinoma › Missouri › St. Louis
Neuroendocrine Carcinoma clinical trials in St. Louis, MO
3 studies for Neuroendocrine Carcinoma are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
RecruitingPhase 1
- Washington University Medicine, St Louis
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RecruitingPhase 1/2
- Washington University School of Medicine (Siteman Cancer Center), St Louis
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- Washington University Infusion Center Pharmacy, St Louis
Neuroendocrine Carcinoma trials in other cities
- Houston, TX6 studies
- New York City, NY6 studies
- Arlington, VA5 studies
- Dallas, TX4 studies
- Los Angeles, CA4 studies
- Washington, DC4 studies
- Columbus, OH3 studies
- Grand Rapids, MI3 studies
- New Haven, CT3 studies
- Denver, CO3 studies
- Atlanta, GA3 studies
- Nashville, TN3 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer73 studies
- Breast Cancer64 studies
- Metastatic Cancer54 studies
- Colorectal Cancer50 studies
- Cancer (all types)46 studies
- Prostate Cancer46 studies
- Lung Cancer39 studies
- Ovarian Cancer38 studies
- Pancreatic Cancer33 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma28 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.